article thumbnail

Product Highlight: DrugBank on Snowflake Marketplace

DrugBank

At DrugBank, we’re dedicated to empowering pharmaceutical researchers with data that drives impactful results. Your Need for Accessible, High-Quality Data—Solved Pharmaceutical research and healthcare innovation demand timely access to comprehensive, up-to-date data. In fact, poor data quality is estimated to cost U.S.

article thumbnail

How GPCR-targeting therapies are advancing the fight against inflammatory disease

Drug Target Review

However, due to its unique biology and structural complexity, PAR2 has proven notoriously difficult for the pharmaceutical industry to effectively target. DT-9046 is currently progressing through pre-IND studies, supported by a robust data package, including head-to-head benchmarks and strong patent protection.

Disease 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Redefining Acceleration of the Drug Development Journey

PPD

By accelerating timelines, anticipating challenges and alleviating bottlenecks, pharmaceutical companies and combined CDMO and CRO partners together can help ensure those potential treatments reach the patients who need them as efficiently as possible.

article thumbnail

WuXi Biologics Unveils WuXiHigh™ 2.0 for Ultra-Concentrated Biologics

The Pharma Data

Meeting the Growing Demand for High-Concentration Biologics High-concentration biologics—generally defined as injectable formulations with protein concentrations exceeding 100 mg/mL—have become a strategic priority for many pharmaceutical developers. WuXiHigh™ 2.0: Pushing the Boundaries With WuXiHigh™ 2.0,

article thumbnail

BeOne Medicines Gains CHMP Backing for BRUKINSA Tablet Formulation

The Pharma Data

By moving to tablets, BeOne estimates a reduction in bottle size by approximately 70%, which not only decreases plastic use but also facilitates more efficient packaging and transportation. These sustainability considerations align with growing global demand for environmentally responsible pharmaceutical manufacturing and distribution.

article thumbnail

Royalty Pharma and Revolution Medicines Sign Funding Deals Worth Up to $2 Billion

The Pharma Data

securing a funding package of up to $2 billion. Rather than diluting ownership or yielding developmental control to a larger pharmaceutical partner, Revolution Medicines is leveraging this funding arrangement to maintain autonomy over its research, development, and eventual commercialization efforts.

article thumbnail

Strategic planning in ADC development: insights from Lonza

Drug Target Review

With a deep understanding of the industry’s complexities and the evolving market needs, he has been instrumental in providing innovative solutions for both biotech startups and large pharmaceutical companies. Each stage must adhere to strict quality and regulatory standards, even before considering fill-finish and packaging.